Infant-Specific Dose of Creon Now Available

Abbott Laboratories June 14 announced that the Food and Drug Administration approved an infant-specific dose of Creon (pancrelipase) in a delayed-release capsule for treating exocrine pancreatic insufficiency (EPI) precipitated by cystic fibrosis (CF).

Most people who have CF also suffer from EPI, which can lead to malnutrition because the lack of enough pancreatic enzymes makes the patients unable to properly digest food, Abbott said in its statement. Most infants who have CF require small doses of pancreatic enzyme replacement therapy (PERT) at every feeding. The new 3,000-unit Creon capsule will enable more precise dosing titration that more closely follows Cystic ...